HIV vaccine - Antigen Express

Drug Profile

HIV vaccine - Antigen Express

Alternative Names: AE-298p; AE-H vaccine

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Antigen Express
  • Class AIDS vaccines
  • Mechanism of Action Helper-inducer T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 08 Feb 2017 HIV vaccine - Antigen Express is available for licensing as of 08 Feb 2017. http://www.antigenexpress.com/ (Antigen Express pipeline, February 2017)
  • 19 Apr 2016 Phase I development is ongoing in USA
  • 03 Dec 2012 Phase-I clinical trials in HIV infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top